Get the latest tech news
Archon emerges from stealth with $20M and ‘antibody cages’ to power up drug development
Archon Biosciences, a biotech startup putting AI to work designing novel biomolecules, has just emerged from stealth with an impressive $20 million in
Archon Biosciences, a biotech startup putting AI to work designing novel biomolecules, has just emerged from stealth with an impressive $20 million in seed funding. His team’s work on generative protein design using AI and other means has been foundational in the fast-evolving industry, and Archon is taking a specific aspect of it to market. These key disease levers are at our fingertips, but we lack the tools to safely and effectively engage them,” explained James Lazarovits, co-founder and CEO of Archon in a press release.
Or read this on TechCrunch
